Error in Table
In the original publication [1], there was a mistake in Table 1 as published. In certain instances, UGT1A1 allele frequencies were inadvertently used to describe phenotype frequencies. The corrected Table 1 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Example UGT1A1 alleles, predicted phenotype function, and frequencies among racial/ethic groups.
Example UGT1A1 Alleles and Predicted Function | ||||||
Star Nomenclature | Variant Type | Allele Function α | ||||
UGT1A1*36 | (TA)5 | Increased Function | ||||
UGT1A1*1 | (TA)6 | Normal Function | ||||
UGT1A1*6 | (211G > A) | Decreased Function | ||||
UGT1A1*28 | (TA)7 | Decreased Function | ||||
UGT1A1*37 | (TA)8 | Decreased Function | ||||
Predicted UGT1A1 Phenotypes Based on Commonly Observed Diplotypes | ||||||
Predicted UGT1A1 Phenotype | Frequently Reported Diplotypes | |||||
Normal Metabolizer (NM) | *1/*1 | |||||
Intermediate Metabolizer (IM) | *1/*28, *1/*6 | |||||
Poor Metabolizer (PM) | *6/*6, *6/*28, *28/*28 | |||||
UGT1A1 Allele Frequencies Among Race/Ethnic Groups µ | ||||||
UGT1A1 | African American/ | Central/ | East Asian | European | Latino | Sub-Saharan African |
*1 | 3% | 54% | 71% | 36% | 21% | 49% |
*6 | <1% | 4% | 15% | <1% | 1% | 0% |
*28 | 37% | 41% | 15% | 32% | 40% | 40% |
*36 | 8% | 0% | 0% | 0% | 0% | 7% |
*37 | 6% | 0% | 0% | <1% | 0% | 4% |
α: UGT1A1 allele function per CPIC and prior investigations [6,11]. β: While allelic diversity continues to be recognized, reference laboratories may only test for certain polymorphisms such as *1, *6, and *28. µ: Table recreated from CPIC UGT1A1 Frequency Table [6,12].
Reference
1. Nelson, R.S.; Seligson, N.D.; Bottiglieri, S.; Carballido, E.; Cueto, A.D.; Imanirad, I.; Levine, R.; Parker, A.S.; Swain, S.M.; Tillman, E.M. et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers; 2021; 13, 1566. [DOI: https://dx.doi.org/10.3390/cancers13071566] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33805415]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details




1 Department of Consultative Services, ARUP Laboratories, Salt Lake City, UT 84108, USA;
2 Department of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL 32610, USA;
3 Department of Pharmacy, Moffitt Cancer Center, Tampa, FL 33612, USA;
4 Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA;
5 Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL 33612, USA;
6 Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA;
7 College of Medicine, University of Florida, Jacksonville, FL 32209, USA;
8 Georgetown University Medical Center, MedStar Health, Washington, DC 20007, USA;
9 Indiana University School of Medicine, Indianapolis, IN 46202, USA;
10 Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL 33612, USA;